Myconormin (Terbinafine)

Terbinafine belongs to the allylamine class and inhibits the fungal enzyme squalene epoxidase. This blockade prevents the synthesis of ergosterol, an essential component of fungal cell membranes, leading to accumulation of toxic squalene and loss of membrane integrity, which ultimately kills the fungal cells.

The dosage of Myconormin is determined by the prescribing healthcare professional based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of terbinafine in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and clinicians usually weigh potential benefits against risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Myconormin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with azole antifungals, terbinafine has a different mechanism—blocking squalene epoxidase rather than inhibiting lanosterol 14α‑demethylase. This often results in a shorter treatment duration for dermatophyte infections and a favorable safety profile, though drug‑interaction potential differs, especially with CYP2D6 substrates.

Myconormin should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Myconormin is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional. Dosing frequency and duration are set by the prescriber based on the infection being treated.

Serious risks include hepatotoxicity, which may present as jaundice, dark urine, or elevated liver enzymes, and severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should promptly report any signs of liver dysfunction or severe skin rash to their clinician.

Myconormin is contraindicated in individuals with known hypersensitivity to terbinafine or any allylamine antifungal. Caution is also advised for patients with pre‑existing liver disease, severe renal impairment, or those taking medications that have major interactions with terbinafine.